
1. Technology overview
Nxtcure Labs is a San Francisco company in Y Combinator's Fall 2026 batch, founded in 2026, with a stated origin at Harvard. It works on running clinical trials end to end with AI, aimed at the cost and time of bringing therapeutics to market.
Its product Galen is an AI-driven contract research organization (CRO) platform with thirteen agents covering the trial lifecycle, including feasibility, site activation, monitoring, safety and biostatistics. Every action with clinical, safety, regulatory or financial consequence stops in a single human review queue. A second branch builds digital twins, which the site lists as in development.
2. Highlighted features & specifications
- Feasibility agent: scores enrollment burden and ranks candidate sites.
- Site activation: tracks contract aging against benchmarks.
- Monitoring: flags key risk indicators and proposes on-site visits for review.
- Safety: routes serious adverse events to a safety physician.
- Biostatistics: prepares disposition and adverse event tables behind a validation gate.
- Review queue: holds every consequential action until a qualified human approves.
3. Potential application
A pharma sponsor could use agent-assisted feasibility to rank trial sites. A CRO could add monitoring agents with human sign-off. A research hospital could prepare safety tables for a multi-site study.
4. Benefits
Thirteen agents work in trial lifecycle order. One human review queue gates every consequential action. Each action carries plain-language reasoning. The site states the design follows the FDA and EMA January 2026 guiding principles for AI in drug development.
5. Market trends & opportunities
Sponsors and CROs look to AI agents to shorten trial operations while regulators publish guidance on AI in drug development. Vietnam and Southeast Asia host a growing number of multinational trial sites. Cost pressure favors automating routine monitoring work.
6. Other information
Nxtcure Labs; San Francisco, USA; founded 2026; Y Combinator Fall 2026. Two branches: Galen autonomous clinical trials and digital twins (in development).
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































